Articles tagged "Rejection"

2020 American Transplant Congress
Th17 Cell Inhibition in a Costimulation Blockade Based Regimen for Vascularized Composite Allotransplantation Using A Non-Human Primate Model
D. P. Moris, A. Atia, M. Rae, M. Song, L. Stempora, F. Leopardi, K. Williams, J. Kwun, W. Parker, A. Cardones, A. D. Kirk, L. C. Cendales
Surgery, Duke, Durham, NC
*Purpose: Vascularized composite allotransplantation (VCA) is challenged by the morbidity of non-specific immunosuppression required to prevent rejection. The use of highly specific biologics has not…
2020 American Transplant Congress
Daratumumab for Desensitization and Antibody Mediated Rejection Treatment in Highly-HLA Sensitized Patients
S. Jordan, R. Vescio, N. Ammerman, M. Toyoda, S. Ge, M. Chu, J. Hou, E. Huang, A. Peng, S. Sethi, R. Najjar, K. Lim, J. Kobashigawa, J. Patel, E. Kransdorf, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly-HLA sensitized (HS) patients have an immunologic barrier to transplantation. ABMR promotes graft loss and poor patient survival. Methods to reduce anti-HLA antibodies are…
2020 American Transplant Congress
Efficacy and Safety of Single-Dose Rabbit Anti-Thymocyte Globulin versus Basiliximab Induction among Pediatric Kidney Transplant Recipients
L. Porini Custodio, S. Stopa Martins, L. Almeida Viana, M. Pontello Cristelli, M. Rika Nakamura, H. Tedesco-Silva, J. Medina-Pestana
Hospital do Rim, Sao Paulo, Brazil
*Purpose: Induction therapy is a standard component of kidney transplant immunosuppression protocols. However, in the pediatric population, there are still uncertainties about the ideal induction…
2020 American Transplant Congress
Significance of Gene Polymorphism on Infectious Complications and Rejection after Liver Transplantation
H. Egawa¹, T. Kato¹, Y. Kotera¹, A. Ohmori¹, G. Shibuya¹, S. Yamashita¹, S. Ariizumi¹, M. Yamamoto¹, T. Ishizuka², Y. Tanaka³, H. Ohdan³
¹Tokyo Women's Medical University, Tokyo, Japan, ²Clinical Labotratory, Tokyo Women's Medical University, Tokyo, Japan, ³Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: Clinical application of gene polymorphism is a key of precision medicine in the field of organ transplantation. Infection and rejection are major factors affecting…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) Levels in Stable Pediatric Kidney Transplant Recipients
M. Waide, J. Carmody, I. G. Restaino
Pediatrics, Eastern Virginia Medical School, Norfolk, VA
*Purpose: Among adult kidney transplant recipients, donor-derived cell-free DNA (dd-cfDNA) has been validated as a highly sensitive biomarker for graft rejection. Unfortunately, few data are…
2020 American Transplant Congress
Late De Novo Donor Specific Antibodies in Steroid Free Immunosuppression and Delayed Graft Function
S. Karhadkar, M. Falz, A. Diamond, A. Di Carlo, O. Timofeeva
Temple University School of Medicine, Philadelphia, PA
*Purpose: Donor Specific Antibodies (DSA) have been implicated in acute and chronic antibody-mediated rejection. Once developed, they tend to be persistent and lead to transplant…
2020 American Transplant Congress
Value of dd-cfDNA When Considering Recipient Ethnicity to Further to Help Risk Stratify Transplant Recipients
A. Langone¹, B. Fischbach², D. Cohen³
¹Vanderbilt Health, Nashville, TN, ²Baylor Scott & White Health, Fort Worth, TX, ³Columbia University, New York, NY
*Purpose: Within the modern era of kidney transplantation, African American (AA) transplant recipients continue to experience disproportionately higher rates of allograft loss. A combination of…
2020 American Transplant Congress
Post-Transplant Rebound and Not Baseline Anti-A Titers are Associated with Acute Antibody-Mediated Rejection in A₂– to B/O Incompatible Kidney Transplantation
V. Kumar, D. Mompoint-Williams, M. Marques, P. MacLennan, M. Mustian, J. Locke
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Decreased antigen expression among blood group A subtype 2 (A2) donor kidneys allows these organs to be considered as universal donors; under the new…
2020 American Transplant Congress
Is Azathioprine the Right Choice in De Novo Lung Transplantation?
A. Chan¹, B. Sirandas¹, A. Carlson¹, C. Truax¹, B. Clark¹, I. Hall², B. Cahill³, L. Smith¹
¹Pharmacy, University of Utah Health, Salt Lake City, UT, ²Nephrology, University of Utah Health, Salt Lake City, UT, ³Pulmonary, University of Utah Health, Salt Lake City, UT
*Purpose: The antiproliferative of choice in lung transplantation (LT) remains controversial. Limited data exists on azathioprine (AZA) dose reductions or the conversion of AZA to…
2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
C. Schardt, R. Yau, A. Burgos, C. Tunwar
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…